Diet and Exercise Failure Trigger
Lifestyle-only management stops working once fasting glucose stays elevated.
- ≥95: Fasting threshold (mg/dL typical trigger)
- ~15–30%: Failure rate (of GDM on lifestyle alone)
- 1–2 wks: Reassessment (glucose log review)
- Meds: Next step (oral or injectable)
When lifestyle control is declared insufficient
Placeholder: repeated above-target readings prompt escalation review.
Metformin Oral Therapy Option
Metformin is a common oral first-line escalation choice.
- Oral: Route (tablet, twice daily typical)
- ↓ Hepatic glucose: Mechanism (output reduction)
- ~25–40%: Failure rate (need added insulin)
- High: Convenience (vs injectable)
Why metformin is often tried first
Placeholder: oral convenience and patient preference favor metformin trials.
Insulin Injectable Therapy Option
Insulin remains the historic gold-standard glycemic control option.
- Injectable: Route (subcutaneous)
- No: Placental crossing (large molecule)
- Titratable: Control (dose adjusted per reading)
- Higher: Burden (injections, monitoring)
Why insulin is still favored in some cases
Placeholder: insulin offers precise titration without placental transfer.
Placental Transfer Consideration
Metformin crosses the placenta while insulin largely does not.
- Yes: Metformin crossing (fetal exposure occurs)
- Minimal: Insulin crossing (large peptide molecule)
- Limited: Long-term data (ongoing follow-up studies)
- Recommended: Shared decision (patient counseling)
Weighing fetal exposure against convenience
Placeholder: transfer profile factors into shared treatment decisions.
Combination Therapy If Needed
Metformin and insulin together when monotherapy underperforms.
- ~25–40%: Combo use (of treated GDM cases)
- Additive: Rationale (complementary mechanisms)
- Intensive: Monitoring (frequent glucose checks)
- Target range: Goal (fasting & postprandial)
Escalating to dual therapy
Placeholder: combination used when single-agent targets are not met.
Placeholder: individualized titration guides the final regimen.